Sequana Medical NVFRA:2SE 31 Return-on-Tangible-Equity is 0.00% as of Jun. 2025. GuruFocus rates FRA:2SE with a GF Score™ of 31/100 and a GF Value™ of €0.19. The stock has 12 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Sequana Medical NV ranks worse than 131925.99% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sequana Medical NV's annualized net income for the quarter that ended in Jun. 2025 was €-36.56 Mil. Sequana Medical NV's average shareholder tangible equity for the quarter that ended in Jun. 2025 was €-41.91 Mil. Therefore, Sequana Medical NV's annualized Return-on-Tangible-Equity for the quarter that ended in Jun. 2025 was N/A%.
The historical rank and industry rank for Sequana Medical NV's Return-on-Tangible-Equity or its related term are showing as below:
FRA:2SE's Return-on-Tangible-Equity is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 4.08 * Ranked among companies with meaningful Return-on-Tangible-Equity only.
Sequana Medical NV (FRA:2SE) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sequana Medical NV Return-on-Tangible-Equity Related Terms
Sequana Medical NV Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sequana Medical NV's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sequana Medical NV Return-on-Tangible-Equity Chart
FRA:2SE vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Sequana Medical NV's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sequana Medical NV Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sequana Medical NV's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sequana Medical NV's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Jun. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 0.00% mean?
Sequana Medical NV (FRA:2SE) has a Return-on-Tangible-Equity of 0.00% as of Jun. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sequana Medical NV and its competitors. According to the industry distribution chart, Sequana Medical NV ranks #999999 out of 758 companies in the Medical Devices & Instruments industry.
Is Sequana Medical NV's Return-on-Tangible-Equity too high?
Sequana Medical NV's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Sequana Medical NV ranks #999999 out of 758 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sequana Medical NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Sequana Medical NV's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sequana Medical NV ranks #999999 out of 758 companies for Return-on-Tangible-Equity. This places Sequana Medical NV in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.08, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sequana Medical NV and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sequana Medical NV's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sequana Medical NV stock overvalued right now?
Sequana Medical NV (FRA:2SE) has a current Return-on-Tangible-Equity of 0.00%. The stock's GF Value™ is €0.19, compared to a current price of €0.51 — trading 169.5% above its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Sequana Medical NV's overall GF Score™ is 31/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sequana Medical NV (FRA:2SE), the current Return-on-Tangible-Equity is 0.00% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sequana Medical NV (FRA:2SE) Overvalued in 2026?
Based on GuruFocus' analysis, Sequana Medical NV stock appears to be overvalued.
The current stock price of €0.51 is trading 169.5% above its estimated GF Value™ of €0.19.
Key valuation signals for FRA:2SE:
Return-on-Tangible-Equity: 0.00%
GF Value™: €0.19 vs. price of €0.51 (169.5% above fair value)
No single metric tells the full story. See the FRA:2SE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sequana Medical NV is a commercial-stage medical device company focused on the development of treatment solutions for the management of fluid overload in liver disease, malignant ascites, and heart failure. The company's products include an alfa pump, which provides a treatment solution for the long-term management of liver refractory ascites and malignant ascites with safety, efficacy, and quality of life benefits demonstrated in multiple clinical studies. The company's geographical segments include Switzerland, Germany, the United Kingdom, France, and the Rest of the world, out of which Germany accounts for the majority of the revenue.
31GF Score
Get the complete analysis for FRA:2SE
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:2SE has been successfully added to your 
